Drug Profile

Research programme: cellular regeneration reprogramming gene therapeutics - Tenaya Therapeutics

Latest Information Update: 09 Oct 2023

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Tenaya Therapeutics
Class Gene therapies; Heart failure therapies
Mechanism of Action Gene transference

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity No

Highest Development Phases

Preclinical Heart failure

Most Recent Events

02 Oct 2023 Pharmacodynamics data from preclinical studies in Heart failure released by Tenaya Therapeutics
04 May 2023 Tenaya Therapeutics has patents pending for cellular regeneration reprogramming gene therapeutics in USA, foreign countries
31 Dec 2022 Tenaya Therapeutics has patent protection for cellular regeneration reprogramming gene therapeutics in USA

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com